Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of IBI305 vs Avastin in Healthy Males
NCT03083990Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2017
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab in metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration up to 85 days and Area Under the Curve from time zero to infinity up to 85 days. Started Mar 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03083990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083990.